Most Read Articles
Natalia Reoutova, 2 days ago

A recent study involving 99 patients in Hong Kong demonstrated that arsenic trioxide (As2O3), used as part of induction and maintenance treatment for newly diagnosed acute promyelocytic leukaemia (APL), is safe and highly effective, achieving 100 percent complete response (CR), 3-year leukaemia-free survival (LFS) and 3-year overall survival (OS) rates. 

Natalia Reoutova, 16 Aug 2019
A recently published study involving 4,517 individuals confirmed the role of BRCA2 mutations in genetic predisposition to oesophageal squamous cell carcinoma (OSCC) among Chinese.

Brentuximab vedotin: A CD30-positive targeted therapy in a heavily pretreated relapsed or refractory Hodgkin lymphoma

19 Sep 2018
Brentuximab vedotin (ADCETRIS®; Takeda Pharmaceuticals) is an antibody-drug conjugate that selectively delivers monomethyl auristatin E, a very potent antimicrotubule agent,into CD30-positive tumour cells, leading to the disruption of the microtubule network. This results in cell cycle arrest and apoptotic death of the CD30-positive cells, making brentuximab vedotin a promising anticancer agent.6,7

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 2 days ago

A recent study involving 99 patients in Hong Kong demonstrated that arsenic trioxide (As2O3), used as part of induction and maintenance treatment for newly diagnosed acute promyelocytic leukaemia (APL), is safe and highly effective, achieving 100 percent complete response (CR), 3-year leukaemia-free survival (LFS) and 3-year overall survival (OS) rates. 

Natalia Reoutova, 16 Aug 2019
A recently published study involving 4,517 individuals confirmed the role of BRCA2 mutations in genetic predisposition to oesophageal squamous cell carcinoma (OSCC) among Chinese.